As such, we believe benefit designs should couple GLP-1 therapies with an evidence-based behavior change program like Omada
Some therapies aim to improve how the body processes nutrients or regulates fat storage
The molecular regulation and pharmacological mechanisms of ferroptosis in disease and therapy are of great significance, and increasing evidence suggests that ferroptosis is associated with the pathogenesis of diabetes-related complications (Table 2)
Additionally, OA severity and inflammatory biomarker levels correlate with increased Fusobacterium abundance, elevated Faecalibacterium prausnitzii levels, and decreased Ruminococcaceae family representation in the gut microbiota (Gaspar et al., 2025
Available from: Wolfe BM, Kvach E, Eckel RH
W., Husaini, Y., Sainsbury, A., Brown, D